From the ∗Program of Immunology and Immunotherapy, Center for Applied Medical Research
†Oncology Department, Clinic University of Navarra
‡Navarra Institute for Health Research (IDISNA), Pamplona
§Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
∥Department of Pathology, Yale University School of Medicine, New Haven, CT.
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. M.F.S. is supported by a Miguel Servet contract from Instituto de Salud Carlos III, Fondo de Investigacion Sanitaria (Spain). I.E.-S. is supported by an AECC Clinical Junior grant. ISCIII MS17/00196, ISCIII PI19/00668, AECC CLJUN20011, NIH grants R03CA219603, R37CA245154, Yale SPORE in Lung Cancer (P50CA196530), Stand Up To Cancer–American Cancer Society Lung Cancer Dream Team Translational Research Grants SU2C-AACR-DT1715, and SU2C-AACR-DT22-17 supported this study.
Reprints: Miguel F. Sanmamed, MD, PhD, Center for Applied Medical Research, Avenida de Pio XII, 55, 31008 Pamplona, Spain. E-mail: [email protected].